RT Article
T1 Challenges for Corporate Ethics in Marketing Genetic Tests
JF Journal of business ethics
VO 77
IS 1
SP 33
OP 44
A1 Williams-Jones, Bryn
A1 Ozdemir, Vural
A2 Ozdemir, Vural
LA English
YR 2008
UL https://ixtheo.de/Record/1785628909
AB Public discussions of ethical issues related to the biotechnology industry tend to treat “biotechnology” as a single, undifferentiated technology. Similarly, the pros and cons associated with this entire sector tend to get lumped together, such that individuals and groups often situate themselves as either “pro-” or “anti-” biotechnology as a whole. But different biotechnologies and their particular application context pose very different challenges for ethical corporate decision-making. Even within a single product category, different specialty products can pose strikingly different ethical challenges. In this paper, we focus on the single over-arching category of “genetic testing” and compare tests for disease susceptibility and drug response. We highlight the diversity of ethical challenges – grouped under the broad categories of “truth in advertising” and “protecting intellectual property” – raised by the commercialization and marketing of these technologies. By examining social and technical differences between genetic tests, and the associated corporate ethics challenges posed by their commercialization, our intent is to contribute to the nascent business ethics literature examining issues raised by the development and marketing of genetic tests.
K1 truth in advertising
K1 intellectual property rights
K1 commercialization
K1 Marketing
K1 Business Ethics
K1 corporate ethics
K1 pharmacogenomics
K1 disease susceptibility
K1 genetic testing
K1 Biotechnology
DO 10.1007/s10551-006-9299-7